Search results
Results from the WOW.Com Content Network
Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO: 4578), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.
In 2011, Astex Therapeutics Limited and SuperGen, Inc. (US) merged. [10] Following the acquisition, SuperGen, Inc. changed its name to Astex Pharmaceuticals, Inc., and began trading under the ticker symbol ASTX on NASDAQ. [11] The combined Astex entities were subsequently acquired by Otsuka Pharmaceutical in October 2013 for around USD $900 ...
Akebia Therapeutics Inc (NASDAQ: AKBA) and Otsuka Holdings (OTC: OTSKY) separately announced to call for licensing and co-development agreement for vadadustat. Otsuka sent a written notice to ...
TOKYO (Reuters) -Japan's Otsuka Pharmaceutical said on Thursday it agreed to pay more than $1 billion to acquire Jnana Therapeutics as it looks to expand its drug pipeline and research base in the ...
Citi analysts forecast 19% earnings growth for the healthcare sector in 2025, up from 4% this year. The analysts point to the stocks' right-sized valuations and a potential improvement in ...
Ono Pharmaceutical's headquarters in Chūō-ku, Osaka, Japan. Ono Pharmaceutical Co., Ltd. (小野薬品工業株式会社, Ono Yakuhin Kōgyō Kabushiki-gaisha) is one of the largest pharmaceutical companies in Japan.
In 2012, to focus on newer, strategic CNS-products, Lundbeck sold a portfolio of non-core products to Recordati S.p.A. (Recordati Rare Diseases). [5] In 2014 Lundbeck acquired Chelsea Therapeutics for up to $658 million. [6] In March 2018, the company acquired Prexton Therapeutics for up to €905 million ($1.1 billion) [7]
Spoilers ahead! We've warned you. We mean it. Read no further until you really want some clues or you've completely given up and want the answers ASAP. Get ready for all of today's NYT ...